glp-1 obesity drug updates today news october 2025 Perspectives from employers on the costs and issues associated with covering GLP-1 agonists for weight loss The next phase of the

doi: 10.14218/JCTH.2024.00271, 23

EMERGING TRENDS AND POTENTIAL PRACTICE IMPLICATIONS Research on GLP-1 agonists suggests that these medications may be effective treatments for conditions beyond diabetes and obesity, suggesting a broad potential impact on health care

For nearly 7 years and over 20 million consultations on our platform since our founding, weve taken this customer-centric approach with all kinds of sensitive, challenging conditions: breaking down barriers to accessing care, whether through raising awareness, removing stigma, improving access channels, and meaningfully lowering the cost of high-quality care

Display ads appear on websites, not in search results

95% CI 0.3, 1.7) or thyroid malignancies (RR 1.4

For instance, GLP-1RAs were demonstrated to reduce the risk of cardiovascular events (5) by decreasing the blood pressure (6), improving microvascular function, and reducing inflammation (7)